Doravirine Use in Treatment-Experienced HIV-Positive Patients

This publication has 6 references indexed in Scilit:

• Prevalence of doravirine-associated resistance mutations in HIV-1-infected antiretroviral-experienced patients from two large databases in France and Italy
  Journal of Antimicrobial Chemotherapy, 2020
• Efficacy and Safety of Doravirine/Lamivudine/Tenofovir Disoproxil Fumarate (DOR/3TC/TDF) in Treatment-Naive Adults With HIV-1 and Transmitted Nonnucleoside Reverse Transcriptase Inhibitor Resistance Mutations
  JAIDS Journal of Acquired Immune Deficiency Syndromes, 2019
• Doravirine: A Return of the NNRTI Class?
  Annals of Pharmacotherapy, 2019
• Switching to Doravirine/Lamivudine/Tenofovir Disoproxil Fumarate (DOR/3TC/TDF) Maintains HIV-1 Virologic Suppression Through 48 Weeks: Results of the DRIVE-SHIFT Trial
  JAIDS Journal of Acquired Immune Deficiency Syndromes, 2019
• Prevalence of predicted resistance to doravirine in HIV-1-positive patients after exposure to non-nucleoside reverse transcriptase inhibitors
  International Journal of Antimicrobial Agents, 2019
• In VitroCharacterization of MK-1439, a Novel HIV-1 Nonnucleoside Reverse Transcriptase Inhibitor
  Antimicrobial Agents and Chemotherapy, 2014